Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated Q3 FY2025 earnings call
November 12, 2025 · fiscal period ended 2025-09
EPS · actual vs est
Revenue · actual vs est
Summary
Generated 2025-11-12
Management highlights
Kris Vaddi discussed strategic decisions to sharpen R&D focus, optimize capital allocation, and align business strategy. Aim to advance two lead candidates into clinical development in 2026: a JAK2V617F selective inhibitor for myeloproliferative neoplasms (MPN) and a KAT6A selective degrader for ER-positive breast cancer. Peggy Scherle reviewed the KAT6A Selective Degrader program, highlighting its potential for best-in-class efficacy and safety differentiation. Sean Brusky discussed the exclusive option agreement with Incyte for the JAK program and the expanded collaboration with AbCellera on degrader antibody conjugates.
Segment performance
No specific financial performance data for product segments provided in the transcript.
Guidance
Both the JAK2V617F Selective Inhibitor and KAT6A Selective Degrader programs are expected to enter the clinic in 2026. The JAK2 program plans to file an IND in Q1 2026 and start Phase I in H1 2026. The KAT6A program is on track for an IND filing in mid-2026 and Phase I start in H2 2026. The option agreement with Incyte includes upfront payments of $35 million and $25 million for nonvoting common stock, with potential additional milestones up to $910 million.
Risks
No detailed discussion of specific risks provided beyond general forward-looking statement disclaimers.
Q&A highlights
Q: Talk about clinical development of mute CALR and KAT6 programs.
A: Kris Vaddi discussed focusing JAK2 on MPN indications like myelofibrosis, polycythemia vera, etc., and KAT6 on ER-positive breast cancer, focusing on monotherapy and combinations.
Q: Preclinical work and differentiation vs competitors.
A: Peggy Scherle mentioned robust preclinical models, KAT6A selectivity, and degrader approach for differentiation.
Q: Competitive landscape for KAT6 and development speed.
A: Peggy Scherle discussed selectivity mitigating toxicity and degrader approach for efficacy; Kris Vaddi mentioned looking to advance rapidly to registrational stages.
Q: Genesis of Incyte deal.
A: Kris Vaddi explained strategic decision to secure capital and align with a leader in MPN space.
Key numbers
Reported versus consensus
Earnings calendar feed
| Metric | Reported | Consensus | Delta | Prior year |
|---|---|---|---|---|
| EPS | $-0.26 | $-0.35 | +25.7% | — |
| Revenue | $6.5M | $20.5M | -68.3% | — |
Transcript
November 12, 2025Full transcript unavailable for redistribution
The structured summary above covers the available call sections. Full transcript text is not included on this page.
Continue exploring
Prior quarters
This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.